A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS)
NCT02525471
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
24
Enrollment
OTHER
Sponsor class
Conditions
ALS
Interventions
DRUG:
RNS60
Sponsor
Sabrina Paganoni, M.D.